生化基因 BIIB 深 沪
已收盘 07-02 16:00:00 美东时间
216.12
+6.380
+3.04%
华盛通- 最 高219.015
- 今 开212.735
- 成交量 115.52万股
- 最 低 210.7464
- 昨 收 209.74
- 总市值 319.07亿
- 52周最高 219.72
- 市盈率 静 24.59
- 换手率 0.78%
- 52周最低 121.05
- 委 比 -89.77%
- 总股本 1.48亿
- 历史最高 468.55
- 量 比 0.80
- 振 幅 3.94%
- 历史最低 61.605
- 每 手 1
- 风险率 23.96%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多三只股票被下调至扎克斯排名第五级（强烈卖出）
渤健（BIIB）、博伊德集团服务公司、点击集团有限公司已被纳入Zacks评级5（强力卖出）名单，反映出基于本年度盈利预期下调形成的负面展望。 关键数据： 1....
06-30 18:25
仑卡奈单抗的转折点已不在临床层面 而在商业层面
核心事件：阿尔茨海默病药物仑卡奈单抗（商品名Leqembi，由卫材研发、渤健联合推广）已获FDA批准，突破此前该领域药物长期商业化失败的行业困境，当前其循证基础...
06-30 15:34
分析师维持对渤健的买入评级 因Spinraza亨廷顿舞蹈症业务势头强劲及管线进展 将目标价上调至256美元
6月25日，Needham明星分析师阿米·法迪亚维持渤健（BIIB）“买入”评级，同时瑞银集团也于同日发布研报维持该股“买入”评级。 关键数据： 1. 阿米·法...
06-30 10:32
美股大行评级 | 康托·菲茨杰拉德大幅上调AMD、英特尔、迈威尔科技、美光、西部数据目标价！Applied、INIO、LFTO、Quantinuum获多家大行首予买入评级
今日重点评级关注：Evercore ISI集团：维持ProQR Therapeutics"跑赢大市"评级，目标价从5美元升至6美元；摩根士丹利：维持霍尼韦尔"标配"评级，目标价从245美元升至490美元
06-30 10:14
渤健：尼达姆与公司高层会议核心要点
Needham分析师阿米·法迪亚在与渤健（Biogen）管理层会面后，将其目标价从255美元上调至256美元，维持“买入”评级。 核心业务相关要点： Spi...
06-29 23:32
Biogen: Key Takeaways From Needham’s Meeting With Top Management
Needham analyst Ami Fadia raised her price target on Biogen (NASDAQ:BIIB) to $256 from $255 and maintained a Buy rating following a meeting with company management. Spinraza HD uptake has been “quite positive,” with demand matching Spinraza’s launch levels, driven by both new and returning patients,...
06-29 23:27
Biogen to present Phase 2 CELIA data for tau-targeting Alzheimer’s drug diranersen at AAIC 2026
Biogen to present Phase 2 CELIA data for tau-targeting Alzheimer’s drug diranersen at AAIC 2026 Biogen outlined new Alzheimer’s disease data disclosures planned for AAIC 2026 in London on July 12-15. Phase 2 CELIA results for diranersen in early Alzheimer’s were previously released as topline findin
06-29 18:59
Needham将渤健目标价上调至256美元 维持买入评级
Needham & Co.将纳斯达克上市药企渤健（BIIB）的目标价上调至256美元，维持买入评级。 关键数据如下： 渤健当前股价为195.34美元...
06-29 18:22
Needham Maintains Buy on Biogen, Raises Price Target to $256
Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $255 to $256.
06-29 18:08
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
Biogen will present new data on its Alzheimer’s disease portfolio at AAIC 2026, including Phase 2 CELIA results for diranersen, a tau-targeting ASO, and emerging data on lecanemab’s subcutaneous administration and real-world use. The presentations highlight Biogen’s leadership in addressing core Alzheimer’s pathologies like amyloid and tau, with a focus on treatment delivery and patient experience.
06-29 10:59
